Bright Minds Biosciences Inc. - common stock - relatórios financeiros (NASDAQ:DRUG)

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use. It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens. The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York.

DRUG

Financials

Bright Minds Biosciences Inc. - common stock

Notícias

Piper Sandler eleva preço-alvo da Bright Minds com avanço nos programas

Jefferies inicia cobertura de Bright Minds com recomendação de compra

BTIG reitera classificação de compra para Bright Minds Biosciences pelo potencial no tratamento de convulsões

H.C. Wainwright eleva preço-alvo da Bright Minds para US$ 145

Bright Minds stock price target raised to $145 by H.C. Wainwright on trial data

Bright Minds Biosciences conclui oferta pública de US$ 175 milhões

Bright Minds Biosciences closes $175 million public offering

Bright Minds Biosciences precifica oferta pública a US$ 90 por ação

Bright Minds Biosciences prices public offering at $90 per share

Bright Minds Biosciences precifica oferta pública de US$ 175 milhões

Bright Minds Biosciences prices $175 million public offering

Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating